ALBRECHT, N. (1992):
Möglichkeiten und Grenzen der Chemotherapie bei Tumorerkrankungen des Hundes – eine Literaturübersicht.
Hannover, tierärztl. Hochsch., Diss.
BOSTOCK, D. E. (1973):
The prognosis following surgical removal of mastocytomas in dogs.
J.Small.Anim.Pract. 14, 27-41
BOYCE, K. L. u. B. E. KITCHELL (2000):
Treatment of canine lymphoma with COPLA/LVP.
J.Am.Anim.Hosp.Assoc. 36, 395-403
BURGAZ, S., B. KARAHALIL , P. BAYRAK, L. TASKIN, F. YAVUZASLAN, I.
BÖKESOY, R. B. ANZION, R. B. BOS, N. PLATIN (1999):
Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics.
Mutat.Res. 439, 97-104
CAMPS-PALAU, M. A., N. F. LEIBMAN, R. ELMSLIE, S. E. LANA, S. PLAZA, J. A.
McKNIGHT, R. RISBON, P. J. BERGMAN (2007):
Treatment of canine mast cell tumors with vinblastine, cyclophosphamide and prednisone: 35 cases.
Vet.Comp.Oncol. 5, 156-167
CHUN, R., L. D. GARRETT, D. M. VAIL (2000):
Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
J.Vet.Intern.Med. 14, 120-124
CHUN, R.A., L. GARRETT, E. MAC EWEN (2001):
Cancer Chemotherapy.
In: S. J. WITHROW u. E. G. MAC EWEN (Hrsg.): Small Animal Clinical Oncology.
3. Aufl. Verlag Saunders, Philadelphia, S. 92-118
DAVIES, D. R., K. M. WYATT, J. E. JARDINE, I. D. ROBERTSON, P. J. IRWIN (2004):
Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
J.Am.Anim.Hosp.Assoc. 40, 124-130
DE WERK, N. A., R. A. WADDEN, W. L. CHIOU (1983):
Exposure of hospital workers to airborne antineoplastic agents.
Am.J.Hosp.Pharm. 40, 597-601
DORN, C. R., D. O. TAYLOR, R. SCHNEIDER, H. H. HIBBARD, M. R. KLAUBER (1968):
Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II.
Cancer morbidity in dogs and cats from Alameda County.
J.Natl.Cancer.Inst. 40, 307-318
DORN, C. R., D. O. TAYLOR, R. SCHNEIDER (1970):
The epidemiology of canine leukaemia and lymphoma.
Bibl.Haematol. 36, 403-415
ECVIM-CA (2007):
Preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine.
2nd version, available at:
http://www.ecvim-ca.org/guide_lines.html.
ENSSLIN, A. S., Y. STOLL, A. PETHRAN, A. PFALLER, H. RÖMMELT, G.
FRUHMANN (1994):
Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.
Occup.Environ.Med. 51, 229-233
ENSSLIN, A. S., R. HUBER, A. PETHRAN, H. RÖMMELT, R. SCHIERL, U. KULKA, G. FRUHMANN (1997):
Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies.
Int.Arch.Occup.Environ.Health 70, 205-208
ERJAVEC, Z., J. H. BEIJNEN, N. H. MULDER (2001):
A taste of taxol.
J.Feline.Med.Surg. 3, 35-36
FRANSMAN, W., R. VERMEULEN, H. KROMHOUT (2004):
Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study.
Ann.Occup.Hyg. 48, 237-244
FRANSMAN, W., R. VERMEULEN, H. KROMHOUT (2005):
Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities.
Int.Arch.Occup.Environ.Health 78, 403-412
FRANSMAN, W., S. PEELEN, S. HILHORST, N. ROELEVELD, D. HEEDERIK, H.
KROMHOUT (2007):
A pooled analysis to study trends in exposure to antineoplastic drugs among nurses.
Ann.Occup.Hyg. 51, 231-239
GARRETT, L. D., D. H. THAMM, R. CHUN, R. DUDLEY, D. M. VAIL (2002):
Evaluation of a 6 month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
J.Vet.Intern.Med. 16, 704-709
GLUE, P. u. R. P. CLEMENT (1999):
Cytochrome P450 enzymes and drug metabolism – basic concepts and methods of assessment.
Cell.Mol.Neurobiol. 19, 309-323
GOLONI-BERTOLLO, E. M., E. H. TAJARA, A. J. MANZATO, M. VARELLA-GARCIA (1992):
Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs.
Int.J.Cancer 50, 341-344
HAHN, K. A., T. C. K. CHAN, W. B. MORRISON, E. A. HAHN (1994):
High-performance liquid chromatographic analysis of doxorubicin and metabolites in canine urine.
J.Am.Anim.Hosp.Assoc. 30, 276-280
HAHN, K. A., G. OGILVIE, T. RUSK, P. DEVAUCHELLE, A. LEBLANC, A.
LEGENDRE, B. POWERS, P. S. LEVENTHAL, J. P. KINET, F. PALMERINI, P.
DUBRENIL, A. MOUSSY, O. HERMINE (2008):
Masitinib is safe and effective fort he treatment of canine mast cell tumors.
J.Vet.Intern.Med. 22, 1301-1309
HAHN, K. A. u. R. C. RICHARDSON (1995):
Cancer Chemotherapy – A veterinary handbook.
Verlag WILLIAMS u. WILKINS, Baltimore
HAMSCHER, G., S. A. I. MOHRING, A. KNOBLOCH, N. EBERLE, H. NAU, I.
NOLTE, D. SIMON (2010):
Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy:
is there an environmental or occupational risk?
J.Anal.Toxicol. accepted for publication November 15th, 2009
HOTTENDORF, G.H. u. S. W. NIELSEN (1967):
Pathologic survey of 300 extirpated canine mastocytomas.
Zentralbl.Veterinarmed.A 14, 272-281
IARC (1975):
Some Aziridines, N-, S- and O-Mustards and Selenium.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 9
IARC (1976):
Some Naturally Occurring Substances.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 9
IARC (1981):
Some Antineoplastic and Immunosuppressive Agents Summary of Data Reported and Evaluation.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 26
IARC (1987):
Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Suppl. 7
KIFFMEYER, T. K., C. KUBE, S. OPIOLKA, K. G. SCHMIDT, G. SCHÖPPE, P. J. M.
SESSINK (2002):
Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety.
The pharmaceutical Journal 268, 331-337
KROMHOUT, H., F. HOEK, R. UITTERHOEVE, R. HUIJBERS, R. F. OVERMARS, R. ANZION, R. VERMEULEN (2000):
Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys.
Ann.Occup.Hyg 44, 551-560
LEIFER, C. E., R. E. MATUS (1986):
Chronic lymphocytic leukemia in the dog: 22 cases (1974-1984).
J.Am.Vet.Med.Ass. 189, 214-217
MARCONATO, L., G. BETTINI, C. GIACOBONI, G. ROMANELLI, A. CESARI, A.
ZATELLI, E. ZINI (2008):
Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
J.Vet.Intern.Med. 22, 1001-1007
MacEWEN, E. G. u. A. I. HURVITZ (1977) :
Diagnosis and management of monoclonal gammopathies.
Vet.Clin.North.Am.Small.Anim.Pract 7, 119-132
McDEVITT, J. J., P. S. LEES, M. A. MC DIARMID (1993):
Exposure of hospital pharmacists and nurses to antineoplastic agents.
J.Occup.Med. 35, 57-60
MEIJSTER, T., W. FRANSMAN, R. VELDHOF, H. KROMHOUT (2006):
Exposure to antineoplastic drugs outside the hospital environment.
Ann.Occup.Hyg. 50, 657-664
MILKOVIC-KRAUS, S., D. HORVAT (1991):
Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs.
Am.J.Ind.Med. 19, 771-774
MOORE, A. S., S. M. COTTER, W. M. RAND, C. A. WOOD, L. E. WILLIAMS, C. A.
LONDON, A. E. FRIMBERGER D. A. L`HEUREUX (2001):
Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
J.Vet.Intern.Med. 15, 348-354
MOORE, M. J. u. E. Erlichman (1998):
Pharmacology of Anticancer Drugs.
In: I. F. Tannock u. R. P. Hill (Hrsg.): The Basic Science of Oncology.
3. Aufl. Verlag McGraw International Editions, New York, S. 370-373
MYERS, N. C., A. S. MOORE, W. M. RAND, J. GLIATTO, S. M. COTTER (1997):
Evaluation of a multidrug chemoterhapy protocol (ACOPA II) in dogs with lymphoma.
J.Vet.Intern.Med. 11, 333-339
PATNAIK, A. K., W. J. EHLER, E. G. MAC EWEN (1984):
Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.
Vet.Pathol. 21, 469-474
PETHRAN, A., R. SCHIERL, K. HAUFF, C. H. GRIMM, K. S. BOOS, D. NOWAK (2003):
Uptake of antineoplastic agents in pharmacy and hospital workers. Part I: monitoring of urinary concentrations.
Int.Arch.Occup.Environ.Health 76, 5-10
POHLOVÀ, H., M. CERNÀ, P. RÖSSNER (1986):
Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs.
Mutat.Res. 174, 213-217
PRIESTER, W. A. (1973):
Skin tumors in domestic animals. Data from 12 United States and Canadian Colleges of Veterinary medicine.
J.Natl.Cancer.Inst. 50, 457-466
RASSNICK, K. M., D. B. BAILEY, A. B. FLORY, C. E. BALKMAN, M. A. KISELOW, J.
L. INTILE, K. AUTIO (2008):
Efficacy of vinblastine for treatment of canine mast cell tumors.
J.Vet.Intern.Med. 22, 1390-1396
ROBERT, J. u. L. GIANNI (1993):
Pharmacokinetics and metabolism of anthracyclines.
Cancer Surv. 17, 219-252
RUSLANDER D. (2005):
Komplikationen der Chemotherapie.
In: M. KESSLER (Hrsg.): Kleintieronkologie.
2. Aufl. Verlag Parey, Stuttgart, S. 139
SARDAS, S., S. GÖK, A. E. KARAKAYA (1991):
Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs.
Toxicol.Lett. 55, 311-315
SELEVAN, S. G., M. L. LINDBOHM, R. W. HORNUNG, K. HEMMINKI (1985):
A study of occupational exposure to antineoplastic drugs and fetal loss in nurses.
N.Engl.J.Med. 313, 1173-1178
SELTING, K. A., G. K. OGILVIE, D. L. GUSTAFSON, M. E. LONG, S. E. LANA, J. A.
WALTON, R. A. HANSEN, A. S. TURNER, I. LAIBLE, M. J. FETTMAN (2006):
Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma.
Am.J.Vet.Res. 67:145-151
SESSINK, P. J. M., K. A. BOER, A. P. H. SCHEEFHALS, R. B. ANZION, R. P. BOS (1992):
Occupational exposure to antineoplastic agents at several departments in a hospital:
Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers.
Int.Arch.Occup.Eviron.Health 64, 105-112
SESSINK, P. J., M. CERNÀ, P. RÖSSNER, A. PASTORKOVÀ, H. BAVAROVÀ, K.
FRANKOVÀ, R. B. ANZION, R. P. BOS (1994):
Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents.
Mutat.Res. 309, 193-199
SIMON, D., S. N. MORENO, J. HIRSCHBERGER, A. MORITZ, B. KOHN, S.
NEUMANN, K. JURINA, S. SCHARVOGEL, C. SCHWEDES, M. REINACHER, M.
BEYERBACH, I. NOLTE (2008):
Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
J.Am.Vet.Med.Assoc. 232, 879-885
SIMON, D., I. NOLTE, N. EBERLE, N. ABBREDERIS, M. KILLICH, J.
HIRSCHBERGER (2006):
Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
J.Vet.Intern.Med. 20, 948-954
STÜCKER, I., J. F. CAILLARD, R. COLLIN, M. GOUT, D. POYEN, D. HÈMON (1990):
Risk of spontaneous abortion among nurses handling antineoplastic drugs.
Scand.J.Work.Environ.Health 6, 102-107
THAMM, D. H., E. A. MAULDIN, D. M. VAIL (1999):
Prednisone and vinblastine chemotherapy for canine mast cell tumor – 41 cases (1992-1997).
J.Vet.Intern.Med. 13,491-497
THAMM, D. H., M.M. TUREK, D. M. VAIL (2006):
Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
J.Vet.Med.Sci. 68, 581-587
VAIL, D. M. (1996):
Mast cell tumors.
In: S. J. WITHROW u. E. G. MAC EWEN, (Hrsg.): Small Animal Clinical Oncology.
Verlag Saunders, Philadelphia, 2nd ed., S. 192-210.
WAKSVIK, H., O. KLEPP, A. BROGGER (1981):
Chromosome analyses of nurses handling cytostatic agents.
Cancer.Treat.Rep. 65, 607-610
ZEMANN, B. I., A. S. MOORE, W. M. RAND, G. MASON, D. M. RUSLANDER, A. E.
FRIMBERGER, C. A. WOOD, D. A. L`HEUREUX, J. GLIATTO, S. M. COTTER (1998):
A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
J.Vet.Intern.Med. 12, 465-470